Market Overview

Zafgen Appoints New Member of Board of Directors; Frank Thomas

Related ZFGN
US Stock Futures Edge Lower Ahead Of ADP Report
Zafgen Completes Enrollment Of Phase 2a Trial Of Beloranib In Hypothalamic Injury-Associated Obesity

Zafgen, Inc. (Nasdaq: ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced the appointment of Frank Thomas to the Company's Board of Directors. In this new role he will also serve as the Chair of the Audit Committee.

Mr. Thomas joins Zafgen with more than 22 years of experience in high growth industries, including the life sciences industry, and significant skill and expertise at the c-suite level. He has served in various executive roles of AMAG Pharmaceuticals, Inc. since 2011, and is currently the Executive Vice President and Chief Operating Officer. Mr. Thomas also served as Interim President and Chief Executive Officer of AMAG from November 2011 to May 2012.

"We are thrilled to welcome Frank Thomas to our Board of Directors, during this important milestone," said Thomas Hughes, Ph.D., Chief Executive Officer of Zafgen. "Frank's extensive experience in the biotechnology industry, combined with significant public company experience will further strengthen our Board, and help us progress as a public company toward our goal of bringing beloranib to market."

"The evolution of Zafgen over the last few years has been impressive to watch and I am looking forward to lending my experiences and expertise to the Company's already exceptional leadership team at such an exciting time," said Mr. Thomas. "I am thrilled to be contributing to the Company's mission to address the significantly underserved population of patients with rare and difficult-to-treat metabolic conditions."

Prior to his time as a senior executive at AMAG Pharmaceuticals', Mr. Thomas served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., a commercial stage medical diagnostics company, from October 2008 to July 2011.

From April 2004 to March 2008, Mr. Thomas spent four years at Critical Therapeutics, Inc., a public biopharmaceutical company, where he began as a Senior Vice President and Chief Financial Officer, and was then promoted to President in June 2006 and Chief Executive Officer in December 2006. Mr. Thomas also held the roles of Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc., a biopharmaceutical company and has been a member of the Board of Directors of the Massachusetts Biotechnology Council. Mr. Thomas earned his B.B.A. from the University of Michigan, Ann Arbor.

Posted-In: News Press Releases

 

Related Articles (ZFGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters